Key result
MRA use in elderly TAVR patients linked to increased death and heart failure.
Why the study?
Morbidity and mortality after TAVR remain high, and the prognostic impact of mineralocorticoid receptor antagonists in this setting remains uncertain.
Does mineralocorticoid receptor antagonist (MRA) use improve clinical outcomes in elderly patients with severe aortic stenosis receiving TAVR?
Cohort
No
Does mineralocorticoid receptor antagonist (MRA) use improve clinical outcomes in elderly patients with severe aortic stenosis receiving TAVR?
Answers are grounded in this paper and cite their sources.
Routine prescription of MRAs in elderly patients receiving TAVR is associated with a negative prognostic impact and might not be recommended.
Morbidity and mortality following trans-catheter aortic valve replacement (TAVR) remain high. Renin-angiotensin system inhibitors improve clinical outcomes in the cohort studied in this work. However, post-TAVR prognostic impact of mineralocorticoid receptor antagonist (MRA), another neuro-hormonal blocker, remains uncertain. Here, we hypothesized that MRA was associated with improved clinical outcomes in elderly patients with severe aortic stenosis receiving TAVR. METHODS: Consecutive patients who received TAVR at our institute between 2015 and 2022 were considered for inclusion. Propensity score matching analysis was performed to match pre-procedural baseline characteristics between those with and without MRA. The prognostic impact of MRA use on the composite primary endpoint consisting of all-cause death and heart failure during the 2-year observational period following index discharge was evaluated. CONCLUSIONS: Routine prescription of MRA might not be recommended in elderly patients with severe aortic stenosis receiving TAVR, given its negative prognostic impact. Optimal patient selection for MRA administration in this cohort needs further study.
No takes yet. Share an insight, caveat, or question.
Imamura et al. (2023) conducted a cohort in Severe aortic stenosis receiving TAVR. Mineralocorticoid receptor antagonist (MRA) vs. No MRA was evaluated on Composite of all-cause death and heart failure (p=0.022). Mineralocorticoid receptor antagonist use in elderly patients receiving TAVR was associated with a negative prognostic impact on all-cause death and heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: